76-year-old Don Wright Has New Goal After Completing 100 Marathons with Myeloma
Doctors told Don Wright he had five years to live when he was diagnosed with multiple myeloma in 2003. Instead of resigning himself to this…
Inês Martins, PhD, managing science editor — 
Articles by Inês Martins
FDA Will Review Amgen’s Request to Expand Use of Xgeva for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has accepted a supplemental biologics license application (sBLA) seeking to expand the currently approved indication of Xgeva…
FDA Approves Darzalex Combo Therapy for Previously Treated Multiple Myeloma Patients
The U.S. Federal Drug Administration has approved a combination of the immunotherapies Darzalex (daratumumab), Pomalyst (pomalidomide) and dexamethasone as a multiple myeloma treatment, according to…
First Patient Dosed in Phase 3 BOSTON Trial Evaluating Selinexor for Multiple Myeloma
Massachusetts–based Karyopharm Therapeutics announced that the first patient was dosed in its pivotal BOSTON Phase 3 clinical trial…
BMT Program at MedStar Georgetown Completes 100th Blood Stem Cell Transplant
John Theurer Cancer Center and MedStar Georgetown University Hospital have announced the completion of the 100th blood stem cell transplant since its joint…
Caris Collaboration to Identify Eligible Participants for NCI-MATCH Trial
Caris Life Sciences is collaborating with the National Cancer Institute (NCI) to identify patients eligible to participate in the Phase 2 NCI-MATCH (Molecular Analysis for Therapy Choice) study,…
$4 Million Perelman Foundation Donation to Kick-start Myeloma Research Initiative
The first research program dedicated to the early detection and prevention of multiple myeloma will be under way soon, thanks to a $4 million Perelman Family…
Trial to Assess NY-ESO SPEAR T-cells as Part of a Combo Therapy Against Multiple Myeloma
Patients with certain kinds of relapsed or refractory multiple myelomas can enroll in a clinical trial assessing a combination of NY-ESO SPEAR T-cells and Keytruda (pembrolizumab), according…
Bluebird to Present Follow-Up Data for CAR T-cell Therapy in Advanced Multiple Myeloma Patients
Patients with advanced multiple myeloma who received three or more lines of therapy have shown promising safety and efficacy…
Non-profit Cancer Therapy Consultant Patient Power Praises District of Columbia Law Limiting Co-pays
The non-profit cancer-therapy consulting group Patient Power is hailing a District of Columbia law that established patient co-pay ceilings on specialty medications for diseases like multiple myeloma.